Jefferies assumed coverage of TG Therapeutics with a Buy rating and price target of $40, up from $35. The analyst sees TG as a “straightforward mid-cap story that currently remains underappreciated by investors.” The company’s lead asset Briumvi provides a differentiated profile versus current aCD20 approvals, the analyst tells investors in a research note. The firm believes Briumvi could gain meaningful market share, reaching above consensus $1B-plus sales in 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TGTX:
- TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
- TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
- TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
- TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
- Biotech Alert: Searches spiking for these stocks today